NOVO HOLDINGS A S
Q2 2025 Form 13-F
HELLERUP, DENMARK
CIK 0001388325
· Institutional investment manager
$1.4B Reported Value Total
Reported value
$1.4B
Quarter over quarter
+5.2%
Holdings
29
Top-10 concentration
73.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Barbara Fiorini
General Counsel
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2025 13F record
Q2 2025 13F filing summary
| Period of report | June 30, 2025 |
|---|---|
| Filed | August 14, 2025 |
| Form | 13F-HR |
| Reported value | $1.4B |
| Positions | 29 |
| Change in reported value | +7.8% |
| New positions | 3 |
| Exited positions | 5 |
| Position turnover | 23.5% |
| Top-10 concentration | 73.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
25 | $1.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
22 | $1.2B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
24 | $1.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
27 | $1.6B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $1.4B |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $1.3B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
34 | $1.7B |
|
Q3 2024 13F
Filed Oct 24, 2024
|
37 | $2.0B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
38 | $1.9B |
|
Q1 2024 13F
Filed May 15, 2024
|
35 | $1.4B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
36 | $1.6B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
40 | $1.4B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
41 | $1.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
47 | $1.5B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
48 | $1.6B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
52 | $2.1B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
54 | $2.0B |
|
Q1 2022 13F
Filed May 16, 2022
|
51 | $1.9B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
48 | $2.1B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
49 | $1.9B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | VTI VANGUARD INDEX FDS | $315.6M | 22.28% |
| 2 | BN BROOKFIELD CORP | $144.2M | 10.18% |
| 3 | ASML ASML HOLDING N V | $132.9M | 9.38% |
| 4 | CRM SALESFORCE INC | $90.0M | 6.36% |
| 5 | MIRM MIRUM PHARMACEUTICALS INC | $76.3M | 5.39% |
| 6 | EWTX EDGEWISE THERAPEUTICS INC | $70.1M | 4.95% |
| 7 | INSM INSMED INC | $68.4M | 4.83% |
| 8 | RXRX RECURSION PHARMACEUTICALS IN | $48.9M | 3.45% |
| 9 | CRNX CRINETICS PHARMACEUTICALS IN | $44.6M | 3.15% |
| 10 | BABA ALIBABA GROUP HLDG LTD | $42.2M | 2.98% |
| 11 | AVBP ARRIVENT BIOPHARMA INC | $40.8M | 2.88% |
| 12 | MRUS MERUS N V | $39.5M | 2.78% |
| 13 | BMRN BIOMARIN PHARMACEUTICAL INC | $36.3M | 2.56% |
| 14 | BPMC BLUEPRINT MEDICINES CORP | $34.0M | 2.4% |
| 15 | VRDN VIRIDIAN THERAPEUTICS INC | $33.3M | 2.35% |
| 16 | PHVS PHARVARIS N V | $30.4M | 2.14% |
| 17 | PCVX VAXCYTE INC | $29.8M | 2.1% |
| 18 | CLDX CELLDEX THERAPEUTICS INC NEW | $24.4M | 1.72% |
| 19 | ZBIO ZENAS BIOPHARMA INC | $21.8M | 1.54% |
| 20 | ELVN ENLIVEN THERAPEUTICS INC | $21.8M | 1.54% |
Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.